Literature DB >> 18414061

Influenza vaccine for high-risk non-elderly adults: a national survey of subspecialists.

Matthew M Davis1, Pascale M Wortley, Serigne M Ndiaye, Anne E Cowan, Amanda D Osta, Sarah J Clark.   

Abstract

Despite long-standing recommendations for non-elderly adults with certain chronic pulmonary, cardiovascular and metabolic conditions to receive influenza vaccine, vaccination rates remain low. Visits to subspecialists represent an important vaccination opportunity, but little is known regarding subspecialists' perceptions related to influenza vaccination. In February 2003, we conducted a cross-sectional mail survey of a random sample (N = 2,007) of board-certified cardiologists, endocrinologists and pulmonologists from the entire United States who provided outpatient care to adults aged 18-64 years, to assess their patterns of and attitudes toward administering influenza vaccine to high-risk, non-elderly patients. The overall response rate was 33%. Among 621 eligible respondents, 483 stocked influenza vaccine in their practice (Stockers) and 138 did not stock the vaccine (Non-Stockers). Pulmonologists were most likely to stock vaccine and strongly recommend vaccination; cardiologists were least likely. Among Stockers, barriers to vaccination varied by subspecialty. Among Non-Stockers, the most common factor in the decision to not stock vaccine was the perception that patients will receive the vaccine elsewhere. Most subspecialists who provide care to a large proportion of high-risk, non-elderly persons recommend influenza vaccination to some degree, particularly pulmonologists. To reduce missed opportunities overall, subspecialists should be encouraged to vaccinate patients who say that they plan to get the vaccine elsewhere. For cardiologists in particular, barriers to stocking influenza vaccine and recommending vaccination more strongly must be addressed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 18414061     DOI: 10.4161/hv.4.3.5516

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  6 in total

1.  A Blueprint for Improving the Promotion and Delivery of Adult Vaccination in the United States.

Authors:  Katherine M Harris; Lori Uscher-Pines; Soeren Mattke; Arthur L Kellermann
Journal:  Rand Health Q       Date:  2012-03-01

2.  Uptake of Influenza Vaccination and Missed Opportunities Among Adults with High-Risk Conditions, United States, 2013.

Authors:  Peng-Jun Lu; Alissa O'Halloran; Helen Ding; Anup Srivastav; Walter W Williams
Journal:  Am J Med       Date:  2015-11-06       Impact factor: 4.965

3.  Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis.

Authors:  Siva H Yedlapati; Safi U Khan; Swapna Talluri; Ahmed N Lone; Muhammad Zia Khan; Muhammad Shahzeb Khan; Ann M Navar; Martha Gulati; Heather Johnson; Seth Baum; Erin D Michos
Journal:  J Am Heart Assoc       Date:  2021-03-13       Impact factor: 5.501

4.  Clinicians' and Pharmacists' Reported Implementation of Vaccination Practices for Adults.

Authors:  Chelsea S Lutz; David K Kim; Carla L Black; Sarah W Ball; Rebecca G Devlin; Anup Srivastav; Amy Parker Fiebelkorn; Carolyn B Bridges
Journal:  Am J Prev Med       Date:  2018-07-24       Impact factor: 5.043

5.  Influenza vaccine coverage and factors associated with non-vaccination among adults at high risk for severe outcomes: An analysis of the Canadian Longitudinal Study on Aging.

Authors:  Katie Gravagna; Christina Wolfson; Giorgia Sulis; Sarah A Buchan; Shelly McNeil; Melissa K Andrew; Jacqueline McMillan; Susan Kirkland; Nicole E Basta
Journal:  PLoS One       Date:  2022-09-30       Impact factor: 3.752

6.  Seasonal influenza vaccination among people with diabetes: influence of patients' characteristics and healthcare use on behavioral changes.

Authors:  A Bocquier; S Cortaredona; L Fressard; F Galtier; P Verger
Journal:  Hum Vaccin Immunother       Date:  2020-03-25       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.